{"doi":"10.1002/ohn.754","title":"A Comprehensive Flow Cytometry Panel for Analysis of Idiopathic Subglottic Stenosis","abstract":"A bstract Objective To present a comprehensive flow cytometry panel for idiopathic subglottic stenosis (iSGS). Study Design Controlled ex vivo cohort study. Setting Tertiary care academic hospital in a metropolitan area. Methods Flow cytometry and single‐cell RNA sequencing were performed on 9 paired normal and scar tissue samples from iSGS patients. Flow cytometry was used to assess the presence of myeloid (CD11b, CD14, CD15, Siglec8), lymphoid (CD3, CD4, CD8, gamma delta [γδ], FOXP3), endothelial (CD31), fibroblast (CD90, SMA), and epithelial (CD326, CK5) markers. Results On flow cytometry, iSGS scar is characterized by an increased presence of myeloid, lymphoid, endothelial, and fibroblast cell types, but a decreased presence of epithelial cells. In the myeloid lineage, iSGS scar samples demonstrated increased CD11b + monocytes ( P < .001), Siglec8 + eosinophils ( P = .03), and CD14 + monocytes ( P = .02). In the lymphoid lineage, iSGS scar demonstrated increased CD3 + T‐cells ( P < .001), CD4 + helper T‐cells ( P < .001), γδ + T‐cells ( P < .001), and FOXP3 + regulatory T‐cells ( P = .002). iSGS scar exhibited specific increases in CD90 + ( P = .04) and SMA + ( P < .001) fibroblasts but decreased CD326 + (E‐cadherin) epithelial cells ( P = .01) relative to normal samples. Conclusion We present a comprehensive flow cytometry panel for iSGS. This flow panel may serve as a common platform among airway scientists to elucidate the cellular mechanisms underpinning iSGS and other upper airway pathologies. Scar iSGS samples demonstrate a distinct cellular profile relative to normal iSGS specimens, exhibiting increased fibroblast, endothelial, and inflammatory cell types but decreased epithelium.","journal":"Otolaryngology","year":2024,"id":457466,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8397,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":642564,"name":"Samuel L. Collins","orcid":"0000-0002-0292-6937","position":1,"is_corresponding":false},{"id":229835,"name":"Yee Chan‐Li","orcid":null,"position":2,"is_corresponding":false},{"id":381363,"name":"Ioan Lina","orcid":"0000-0002-8619-7312","position":3,"is_corresponding":false},{"id":381368,"name":"Alexander Gelbard","orcid":"0000-0003-0078-1305","position":4,"is_corresponding":false},{"id":381366,"name":"Kevin Motz","orcid":"0000-0002-9255-7265","position":5,"is_corresponding":false},{"id":240456,"name":"Alexander T. Hillel","orcid":"0000-0001-8471-5449","position":6,"is_corresponding":false},{"id":1011463,"name":"Raymond J. So","orcid":"0000-0003-1004-7606","position":0,"is_corresponding":true}],"reference_count":37,"raw_metadata":null,"created_at":"2026-07-19T02:03:37.136946Z","pmid":"38606634","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}